상세 보기
초록
Background: Dacomitinib is a second-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Pre-clinical data suggest that intermittent pulsatile dosing of dacomitinib may result in inhibition of EGFR T790M. Methods: We evaluated safety, pharmacokinetics and efficacy of intermittent pulsatile dacomitinib in both molecularly unselected patients and patients with lung cancers harboring EGFR T790M (Clinical Trial Registration Number NCT01858389). Results: Thirty-eight patients were treated on study with pulse dacomitinib; sixteen with EGFR T790M in Cohort A and 22 who were not molecularly selected in Cohort B. One patient out of 16 patients in Cohort A had a partial response to study therapy (ORR 6.3%, 95% CI 0.2-30.2%). The median progression-free survival (PFS) in Cohort A was 2.3 months and median PFS in Cohort B was 1.6 months. The adverse event profile was similar to standard daily dose dacomitinib with the most frequent treatment-related toxicities occurring in > 20% of patients being diarrhea, rash, stomatitis, nausea, dry skin, paronychia, fatigue, and decreased appetite. Conclusion: Intermittent pulsatile dacomitinib is safe and relatively well tolerated but is not effective in patients that harbor EGFR T790M or in unselected patients with non-small cell lung cancer.
키워드
- 제목
- Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers
- 저자
- Yu, Helena A.; Ahn, Myung-Ju; Cho, Byoung Chul; Gerber, David E.; Natale, Ronald B.; Socinski, Mark A.; Giri, Nagdeep; Quinn, Susan; Sbar, Eric; Zhang, Hui; Giaccone, Giuseppe
- 발행일
- 2017-10
- 유형
- Article
- 저널명
- Lung Cancer
- 권
- 112
- 페이지
- 195 ~ 199
- 언어
- ENG
- 출판사
- Elsevier BV
- 발행국가
- 아일랜드
- 분량
- 5 페이지
- ISSN
- E 1872-8332
P 0169-5002